Daily Management Review

After Emergence Of Blood Clot Reports, J&J Reportedly Asked Vaccine Rivals For Help


After receiving complaints of reports of blood clots, Johnson & Johnson had asked for help from its three rival Covid-19 vaccine makers to investigate the reports. However, the company was refused help by both Pfizer and Moderna, claimed a report published by the Wall Street Journal on Friday quoting information from people familiar with the matter.
AstraZeneca however agreed to help out J&J, the WSJ report claimed.
Another proposal that J&J had made to its Covid-19 vaccine making rivals was to form an informal alliance between them so that it would help the companies to speak up in one voice as an industry representative about the safety of the vaccines while also trying to address the concerns among the public about the blood-clot cases, claimed the Journal report quoting sources.
There were no comments on the WSJ report made by a Pfizer spokesperson in a statement to the media. "Pfizer embraces opportunities for scientific exchange when we can make a meaningful contribution that is not being represented by other groups or regulators," the spokesperson said. "We have and will continue to collaborate with other vaccine makers as appropriate as we all fight against this deadly pandemic."
No comments on the WSJ report were made by Moderna and AstraZeneca.
"The safety of the patients who use our products is our top priority," J&J said in a statement issued to the media about the WSJ report and added that there is active cooperation from the company with authorities in the US and Europe. The Cvoid-19 pandemic has resulted in "unprecedented collaboration and sharing of publicly available data and information", the company also noted and added: "we believe collaborative scientific exchange can lead to more robust answers to questions."
It was just three days ago that the US Centers for Disease Control and Prevention as well as the country’s Food and Drug Administration had made recommendations for temporarily halting the emergency use of the J&J vaccines against Covid-19 after there were reports of six cases in the US of people who were administered the vaccine developing a rare and severe type of blood clot.

Women between the ages of 18 and 48 were comprised of the people reported in all of the six cases of negative health after effects of the J&J vaccine, the agencies said in a statement. It also said that symptoms among the people were seen between six and thirteen days of being vaccinated. The two US agencies said that the recommendation to pause was taken out of "an abundance of caution," they added, and these cases "appear to be extremely rare."